Phesgo drug class
WebHER2 is found on the outside of some cancer cells and it stimulates their growth. Phesgo® belongs to a group of cancer drugs called monoclonal antibodies. Monoclonal antibodies are sometimes called targeted therapies because they work by ‘targeting’ specific proteins (receptors) on the surface of cells. Phesgo® locks onto the HER2 protein. WebOct 13, 2024 · Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) is a combination of HER2 /neu receptor antagonists and an endoglycosidase indicated for use in …
Phesgo drug class
Did you know?
WebMar 1, 2024 · • you have ever had chemotherapy medicine from the class called anthracycline, e.g. doxorubicin – these medicines can damage heart muscle and increase the risk of heart problems with PHESGO; • you have ever had radiotherapy to the chest area prior to treatment with PHESGO as it can increase the risk of heart problems; or WebPertuzumab and trastuzumab belong to a class of medications known as monoclonal antibodies. These medications work by slowing or stopping the growth of cancer cells.
WebTrade Name (s): Phesgo ® Pertuzumab/trastuzumab/hyaluronidase is the generic name for the trade name drug Phesgo. In some cases, health care professionals may use trade name or the generic name when referring to the drug. Drug Type: Pertuzumab, trastuzumab, and hyaluronidase is a targeted therapy. WebMar 18, 2024 · Phesgo 600 mg/600 mg solution for injection Active Ingredient: trastuzumab, pertuzumab Company: Roche Products Limited See contact details ATC code: L01XY02 About Medicine Prescription only medicine Healthcare Professionals (SmPC) Patient Leaflet (PIL) This information is for use by healthcare professionals Last updated on emc: 18 Mar …
WebJun 29, 2024 · Phesgo contains a fixed-dose combination of pertuzumab and trastuzumab with hyaluronidase for injection under the skin. The therapeutic components in Phesgo …
WebIndications Early Breast Cancer. PHESGO ® (pertuzumab, trastuzumab, and hyaluronidase-zzxf) is indicated for use in combination with chemotherapy for. the neoadjuvant …
WebPHESGO ™ is a prescription medicine approved for use in combination with docetaxel in adults who have HER2-positive breast cancer that has spread to different parts of the body (metastatic) and who have not received anti-HER2 therapy or chemotherapy for metastatic breast cancer. What should I know about side effects with PHESGO? healthcare screening formWebPhesgo consumer information Check interactions Pricing & coupons Side effects Dosage information During pregnancy FDA approval history Drug class: HER2 inhibitors En español Related treatment guides Breast Cancer Drug Interaction Classification Further information go live on twitter desktopWebDRUG INTERACTIONS 8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy 8.2 Lactation 8.3 Females and Males of Reproductive Potential 8.4 Pediatric Use 8.5 Geriatric Use 11 ... go live or goes liveWebU.S. Food and Drug Administration (FDA)-Approved Indications ... the U.S. Food and Drug Administration approved Phesgo, a fixed-dose combination of two HER2/neu receptor … health cares collapse takes tollWebPhesgo® contains two separate monoclonal antibodies, trastuzumab and pertuzumab. Previously, trastuzumab and pertuzumab were used separately or in combination to … healthcare screening guidelinesWebSep 30, 2024 · The U.S. Food and Drug Administration (FDA) has approved trastuzumab, pertuzumab, and trastuzumab + pertuzumab subcutaneous fixed dose combination (PHESGO) as treatment for HER2 positive breast cancer. The FDA has also approved hormonal therapies as treatment for hormone receptor positive breast cancer. . Study … healthcare screening recommendationsWebInjection time. The first dose of PHESGO takes about 8 minutes to inject. Other doses take about 5 minutes to inject. Your healthcare team will wait at least 30 minutes after the first dose, and at least 15 minutes after each following dose, to check for any reactions. If side effects occur, your healthcare provider may slow, delay, or stop ... go live or go life